Select a Region North America

Macroeconomic Factors Impact Cash Flow for Pharma

Worldwide inflation, ongoing effects of the COVID-19 pandemic and other macroeconomic factors continue to negatively impact established brands at a time when pharma companies need their positive cash flow the most to continue funding R&D.

Leading experts Ed Cox and Sean Rapson break down the facts and share their insight how to leverage new models like EVERSANA™ REIGNITE Commercialization, to properly invest in your established brands and maximize revenue potential.

Watch this 8 minute video or schedule a meeting with our experts. Or explore more information about Established Brands and our solutions.

Author
Edward Cox
Executive Vice President, Strategic Alliances & Global Head of Digital Medicine

Widely recognized as a preeminent thought leader in digital therapeutics, Ed joins EVERSANA from Dthera Sciences, where as its CEO, he earned the FDA’s Breakthrough Device designation for a digital therapeutic to treat the…

Sean Rapson
Managing Director

Sean brings experience gained through various internal commercial roles at a premier biopharmaceutical company and as a consultant advising leading biopharmaceutical clients. His focus is on defining and delivering corporate, portfolio, and brand-level vision…